Form 8-K - Current report:
SEC Accession No. 0001140361-25-010064
Filing Date
2025-03-24
Accepted
2025-03-24 17:27:16
Documents
19
Period of Report
2025-03-21
Items
Item 3.02: Unregistered Sales of Equity Securities
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ef20045985_8k.htm   iXBRL 8-K 44481
2 EXHIBIT 1.1 ef20045985_ex1-1.htm EX-1.1 218474
3 EXHIBIT 4.1 ef20045985_ex4-1.htm EX-4.1 138096
4 EXHIBIT 4.2 ef20045985_ex4-2.htm EX-4.2 114969
5 EXHIBIT 5.1 ef20045985_ex5-1.htm EX-5.1 20469
9 image0.jpg GRAPHIC 34391
10 image1.jpg GRAPHIC 12386
  Complete submission text file 0001140361-25-010064.txt   864800

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA ird-20250321.xsd EX-101.SCH 3976
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE ird-20250321_lab.xml EX-101.LAB 21966
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ird-20250321_pre.xml EX-101.PRE 16041
21 EXTRACTED XBRL INSTANCE DOCUMENT ef20045985_8k_htm.xml XML 4216
Mailing Address 8 DAVIS DRIVE SUITE 220 DURHAM NC 27709
Business Address 8 DAVIS DRIVE SUITE 220 DURHAM NC 27709 248-681-9815
Opus Genetics, Inc. (Filer) CIK: 0001228627 (see all company filings)

EIN.: 113516358 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-34079 | Film No.: 25765176
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)